Abstract
Tumour metastasis is the major cause of morbidity and mortality from colorectal cancer. While improvements in duality of life and patient survival have been made over the past 10 years, the majority of patients with metastatic colorectal cancel will die from their disease. As knowledge of the biology of colon cancer and its invasion/metastasis programme evolve, this presents new therapeutic opportunities for pharmacological and genetic intervention. This review discusses the current approaches to metastatic colorectal cancer therapy, details genomic and biological variance between primary and metastatic tumours, and highlights approaches for harnessing these differences to improve therapy. (C) 2000 Elsevier Science Ltd. All rights reserved.
Original language | English |
---|---|
Pages (from-to) | 1706-1712 |
Number of pages | 7 |
Journal | European Journal of Cancer |
Volume | 36 |
Publication status | Published - 2000 |
Keywords
- colorectal cancer
- metastasis
- developmental therapeutics
- gene therapy
- RECOMBINANT VACCINIA VIRUS
- CYTOSINE DEAMINASE GENE
- herpes simplex virus
- CARCINOEMBRYONIC ANTIGEN PROMOTER
- comparative genomic hybridization
- THYMIDYLATE SYNTHASE GENE
- wild type P53
- liver metastases
- lung cancer